← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2009First marketed drug
Jan 1, 2009First NDA
Aug 12, 2013Last known activity
Mar 17, 2026
Timeline
1990s
- Apr 4, 1997
delavirdine— NDA Secondary Org
- Apr 4, 1997
delavirdine— NDA Organization
2000s
- Jan 1, 2009
ViiV Healthcare— Founded
2020s
- Jul 2, 2020
fostemsavir— Marketing Organization
Drugs by trial phase (95 distinct, 284 trials)
Phase 4 (29 own, 0 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Phase 1 (46 own, 0 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- AIDS Dementia Complex
- Coinfection
- Communicable Diseases
- Cytomegalovirus Infections
- Dementia
- Epstein-Barr Virus Infections
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis C, Chronic
- HIV-Associated Lipodystrophy Syndrome
- HIV Infections
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Lipodystrophy
- Liver Diseases
- Malaria
- Neurocognitive Disorders
- Papilloma
- Renal Insufficiency
- Tuberculosis
- Viremia
Marketed drugs (10)
Recent trials (50)
- NCT04233047Lead sponsorN/A—
- NCT03462810Study directorN/A—
- NCT03462810Lead sponsorN/A—
- NCT03847376CollaboratorN/A—
- NCT04233047Study directorN/A—
- NCT07275606Lead sponsorPhase 1/Phase 2Mar 17, 2026
- NCT07199335CollaboratorPhase 4Nov 30, 2025
- NCT07202546Lead sponsorPhase 2Nov 28, 2025
- NCT06967753CollaboratorPhase 4Jul 31, 2025
- NCT07053384Lead sponsorPhase 1Jul 10, 2025
- NCT07066722Lead sponsorPhase 1Jul 7, 2025
- NCT06970223Lead sponsorPhase 1Apr 22, 2025
- NCT06646562CollaboratorPhase 4Mar 3, 2025
- NCT06497465CollaboratorPhase 3Jan 31, 2025
- NCT06741397Lead sponsorPhase 2Dec 20, 2024
Details
- Founded
- London, GB Jan 1, 2009
- First NDA
- Aug 12, 2013
- Last known activity
- Mar 17, 2026
Designations held
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval